Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 253

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 253
---
 value of the business at the end of the projection period to arrive at an estimate of value.

Newbridge performed a DCF Analysis of the estimated future unlevered free cash flows attributable to the three subsidiaries of Longevity for the fiscal years of 2023 through 2032. In applying the DCF Analysis, Newbridge relied on the Financial Projections prepared by the LBI management team that took into consideration, potential timing of U.S. FDA approval of its various key products (see below), a commercialization and sales schedule, and a clinical development budget.

| 126 |

While Newbridge has reviewed the financial model to determine the reasonableness of the financial model’s assumptions, neither Newbridge,FutureTech norLBI can guarantee that the milestones in the model can be achieved in the timeframes suggested.

The Management team of LBI believes that it may be able to U.S. FDA approval for the following lead pipeline candidates in the following order:

| ● | Aegeria                          
 | Soft Tissue Repair | (Q1-2028) |

| ● | Reflow                                   
 RVO | Retinal Vein Occlusion | (Q4-2029) |

| ● | Aureva                              
 | Stoke Care / Recovery | (Q1-2028) |

The management team ofLBI created a commercialization and sales schedule for all three subsidiaries, based upon market sizing and market penetration levels.

The management team ofLBI included in their financial model assumptions that in the first several years of operations, (specifically in 2024 / 2024 / 2025), the combined companies expect to have an accumulated negative EBITDA of approximately $24.4M.

When creating a DCF for pre-regularly approved (U.S. Food and Drug Administration) products, Newbridge applies an additional discount factor that is calculated by dividing target’s expected POS or LOA based on their clinical phase, using as a source the study “Clinical Development Success Rates and Contributing Factors 2011-2020” by BIO, Informa Pharma Intelligence and QLS Advisors.

| ● | Aegeria                                    
 | Soft Tissue Repair – LOA for Dermatology |

| ○ | Implying                                                                             
 a Phase II to Approval POS of 20.47%, which we used as the estimated POS for LB-101. |

| ● | Reflow                                                   
 RVO | Retinal Vein Occlusion – LOA/POS for Ophthalmology |

| ○ | Implying                                                                                
 a